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Neurological DisorDers – Health care use & Policy studies
PND11
NatioNal estimates of PrevaleNce aND PatterNs of PsycHotroPic 
PolyPHarmacy amoNg elDerly iNDiviDuals witH ParkiNsoN’s Disease 
iN NursiNg Home aND Home HealtHcare settiNgs iN tHe uNiteD states
Bhattacharjee S, Goldstone L, Warholak T
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Objectives: Some elderly individuals with Parkinson’s disease (PD) may suffer 
from more than one psychiatric comorbidity, which necessitates the use of concur-
rent psychotropic medications. To the best of the author’s knowledge there are no 
nationally representative estimates of psychotropic polypharmacy among elderly 
individuals with PD in the United States. Therefore, the primary objective of this 
study was to examine the prevalence and patterns of psychotropic polypharmacy 
among elderly individuals with PD. MethOds: A retrospective, cross-sectional 
study design with 2004 National Nursing Home Survey (NNHS) and 2007 National 
Home and Hospice Care Survey (NHHCS) data was used. The analytic sample 
included elderly (age ≥ 65 years) individuals with PD (identified by ICD-9-CM code 
of 332.xx). Antidepressants, antipsychotics, sedative/hypnotics, and anti-anxiety 
medications constituted the psychotropic medication classes. Concurrent use of 
two or more psychotropic medications was classified as psychotropic polyphar-
macy. National estimates of psychotropic medication use were obtained by using 
SAS survey procedures. Results: National estimate of approximately 93,648 [95% 
Confidence Interval (CI), 86535 – 100,761] and 37,439 (95% CI, 25,910 – 48,968) elderly 
individuals with PD resided in nursing homes and home health settings respec-
tively. Among elderly nursing home residents with PD, the nationally representative 
prevalence of psychotropic polypharmacy was 26.28% (95% CI, 22.81% – 29.75%), 
whereas, it was 21.36% (95% CI, 8.12% – 34.6%) in the home health setting. Use of 
antidepressant medications constituted the majority of the psychotropic medica-
tion use among both nursing home (48.91%, 95% CI, 44.9% – 52.8%) and home health 
(40.98%, 95% CI, 25.37% - 56.61%) residents with PD. Nearly one-third (31.26%, 95% 
CI, 27.6% - 34.9%) nursing home residents with PD were prescribed antipsychotic 
medications among whom less than one-fourth had a documented psychotic diag-
nosis. cOnclusiOns: These findings underscore the importance of evidence-based 
prescribing when psychotropic medications are used in elderly individuals with PD 
to reduce unnecessary polypharmacy.
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Objectives: Teriflunomide oral tablets were approved in the United States (US) in 
September 2012 for the treatment of relapsing remitting multiple sclerosis (RRMS). 
The objective of this study is to assess the characteristics of RRMS patients tak-
ing Teriflunomide tablets in 2012 in the US. MethOds: A large US administra-
tive retrospective claims database was used to identify patients diagnosed with 
RRMS and were prescribed Terfilunomide between September 2012 to December 
2012 were included in the study. All patients were ≥ 18 years of age and continu-
ously enrolled in the same health plan for a year. Descriptive statistics and chi-
square tests were performed on the data and statistical significance level was set 
a priori at 0.05. Results: There were a total of 157 patients that met the study 
inclusion criteria. Of these, 114 (72.6%) were females, mean age was 50.9±9.7 years, 
and females were older than males (51.4 vs 49.5 years) with no statistical signifi-
cance different between them. Thirty three percentage of the patients were from 
Midwest, 30.6% were from East, 26.1% from south and 10.2% from West of the USA. 
Twenty eight percentage of the patient’s prescription was under their health plan 
formulary and received an average of supply of 29.4 ± 8.8 days. Majority (61.1%) of 
the patients was under group coverage and 55.4% of patients were diagnosed with 
having mental health problems. Males enrolled continuously (60.21 ±21.8 vs 52.5 ± 
28.9 months) much longer than females in the same health plan. But, females had 
a higher number of total claims (514.9 ± 443 vs 391.4 ± 307.6) during the enrollment 
period. cOnclusiOns: Majority of the patients taking Terfilunomide was females 
and had more number of claims related to MS than males. And, majority of the 
patients were dispensed Terfilunomide for only one month supply.
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ObjectivOs: Llevar a cabo una revisión de la evidencia disponible de costo-efec-
tividad de la terapia inmunomoduladora con medicamentos modificadores de la 
enfermedad aprobados en Colombia para el tratamiento de la Esclerosis Múltiple 
(EM) tipo recaída remisión. MetOdOlOgíAs: Búsqueda sistemática de evaluaciones 
económicas en las bases de datos PUBMED y EMBASE a través de una estrategia 
de búsqueda estructurada en pacientes adultos con diagnóstico confirmado de 
esclerosis múltiple tipo recaída remisión bajo tratamiento con IFN B, Acetato de 
Glatirámero, Natalizumab y/o fingolimod. Se incluyeron estudios de costo-efec-
tividad y/o costo-utilidad y se excluyeron estudios de análisis de impacto presu-
puestal y de costo de la enfermedad. Se llevó a cabo la evaluación de la calidad 
de los estudios mediante la herramienta Quality of Health Economics Studies 
(QHES) ResultAdOs: Se analizaron 30 estudios identificados que contenían los cri-
terios de inclusión preestablecidos. El 83% fueron desarrollados en Estados Unidos 
y Europa. El 90% de los estudios publicados corresponde a países desarrollados y el 
10% a países en vía de desarrollo. Los principales resultados en salud fueron Calidad 
de Vida, número de recaídas evitadas y años libres de recaídas. Siendo la EM una 
information included date of purchase; quantity of units purchased; unit price; 
responsible body; form of acquisition (tendering or waivered emergency purchase) 
and justification for purchase (regular use or health litigation). Unit prices were 
deflated to December 2013 by the IPCA (Brazilian Pricing Index) to allow compara-
bility and evaluation of trends. Results: More than 47 million units of medicines 
for AD were bought and expenditures reached 90.1 million reais, with rivastigmine 
purchases in the forefront. Medicines not present in the guidelines represented 
3% of expenditures and purchases associated to health litigation were negligi-
ble. The Ministry of Defense was the largest buyer of medicines not included in 
the guidelines. Over the entire period, a reduction of corrected weighted average 
prices of PCDT and non-PCDT medicines was observed. cOnclusiOns: We noted 
a significant increase in the amount of medicine purchases over time. Updates on 
PCDT, changes in medicines financing and procurement, and the establishment of 
Productive Development Partnerships may have contributed with the scale-up of 
AD treatment availability. The reduction of lawsuits demanding medicines suggests 
normalization of medicine procurement mechanisms for these drugs. The resources 
consumed with non-PCDT medicines increased in the period.
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Objectives: This systematic review is conducted to investigate the impact of 
rasagiline on economics of care for patients with PD. MethOds: A literature 
search using the online version of Index Medicus identified relevant publications, 
abstracts, technology assessments of rasagiline using search terms; title: rasagiline 
and Parkinson* AND economic OR budget OR cost; language: English; publication 
dates 01/01/2009 to 01/30/2015. In addition, websites were searched for health tech-
nology assessments. Results: A total of 15 studies (7 cost models, 1 economic 
database analysis and 7 resource utilization studies) were eligible for inclusion. The 
four US based cost effectiveness models suggest that initiating treatment (tx) with 
rasagiline had lower costs ($1600) and higher expected QALYs (0.0608) over 5 years 
compared with ropinirole XL; total medical and pharmacy costs were $115,653 less 
per patient for rasagiline vs standard of care over 25 years. In addition, initiating tx 
with rasagiline was cost effective relative to generic ropinirole (CE ratio of $25,939 
per QALY); and a US cost-utility analysis showed adjunctive use of rasagiline with 
levodopa and carbidopa/levodopa/entacapone were both dominant strategies over 
levodopa monotherapy. In a Mexico-based model using a 5-year time horizon the 
cost per QALY for rasagiline was $33,400 (Mexico peso). Medication and adverse 
event costs were also evaluated in a Russian model. Observational study results (8) 
were based on US, UK and Croatian data. US studies results comparing rasagiline 
to selegiline show fewer hospitalizations (1.119 vs 2.113, p= 0.013) shorter length 
of stay (2.762 vs 5.556, p= 0.014) and lower likelihood of emergency department 
visits (OR= 0.791, 95% CI 0.677 to 0.926) with rasagiline. cOnclusiOns: Rasagiline 
was found cost effective across multiple countries compared with commonly used 
PD medications. The beneficial impact of rasagiline on resource utilization in the 
observational studies highlights the real world potential of rasagiline to result in 
economic benefits to healthcare systems.
Neurological DisorDers – Patient-reported outcomes & Patient Preference 
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Objectives: To estimate the levels of adherence and persistence of patients 
with Relapsing-Remitting Multiple Sclerosis (RRMS) and treated with platform 
therapies in Brazil. MethOds: DATASUS, a nation-wide, anonymized, health-
care claims database was used as primary data source. Naïve patients starting 
on one of the platform therapies for RRMS, between January and June 2013 were 
followed for at least 13 months (up to 18), until September 2014) after the first 
entry in DATASUS (considered for this analysis as treatment initiation). Therapies 
included intramuscular (IM) interferon beta-1a (IFNβ -1a), subcutaneous (SC) 
IFNβ -1a, IFNβ -1b, and glatiramer acetate (GA).Adherence was measured as medi-
cation possession ratio (MPR), calculated as the proportion of months patients 
possessed their therapies independently of drug change until the end of the ana-
lyzed period, where MPR> 0.80 was considered adherent. Persistence was time in 
months from initiation date until a 30-day gap in therapy or the last claim during 
follow-up. Chi-square assessed the association between treatments and time on-
therapy. Median difference between MPR was assessed through Kruskal-Wallis’ 
Method. Analyses were performed using R, version 3.1. Results: Total number 
of patients was 1,052: IM-IFNβ -1a (N= 351, 33.4%); IFNβ -1b (N= 145, 13.8%); GA 
(N= 264, 25.1%); and SC-IFNβ -1a (N= 292, 27.8%). MPR> 0.80 was significantly higher 
(p< 0.001) in the IM-IFNβ -1a group (71.8%) versus IFNβ -1b (58.6%), GA (65.5%), and 
SC-IFNβ -1a (63.7%). There were no consistent differences in persistence between 
the groups. cOnclusiOns: While there are limitations in measuring adherence 
even in controlled trials, MPR seems to be appropriate in real life scenario. Patients 
initiating treatment with IM-IFNβ -1a showed better adherence than those initiat-
ing with other platform therapies for RRMS in Brazil. The literature reports simi-
lar efficacy and safety profile among platform therapies, however, they differ in 
terms of administration route and dose scheduling. Better adherence results for 
IM-IFNβ -1a may be associated with dosing regimen and convenient administration 
from an auto-injector device.
